Royalty Pharma (RPRX) Short-term Investments (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Short-term Investments data on file, last reported at $21.9 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 80.99% year-over-year to $21.9 million; the trailing twelve-month figure through Mar 2026 stood at $21.9 million (up 80.99% YoY), and the FY2025 full-year result was $18.8 million, down 67.7% from the prior year.
• Short-term Investments improved to $21.9 million in Q1 2026, from $18.8 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $409.3 million in Q3 2022 to a low of $5.3 million in Q3 2023.
• A 5-year average of $76.1 million and a median of $24.4 million in 2022 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments slumped 98.71% in 2023 and soared 815.09% in 2024, its largest moves.
• Tracing RPRX's Short-term Investments over 5 years: stood at $24.4 million in 2022, then fell by 25.06% to $18.3 million in 2023, then surged by 218.03% to $58.2 million in 2024, then plunged by 67.7% to $18.8 million in 2025, then increased by 16.49% to $21.9 million in 2026.
• Business Quant data shows RPRX's Short-term Investments at $21.9 million in Q1 2026, $18.8 million in Q4 2025, and $16.1 million in Q3 2025.